Amgen to invest additional $300M in U.S. manufacturing network

Amgen (AMGN) announced plans to invest an additional $300M in its U.S. manufacturing network to further advance U.S.-based production capacity, enhance next-generation technologies and support a reliable supply of medicines for patients. Amgen’s expansion of its biologics manufacturing facility in Puerto Rico will strengthen existing advanced manufacturing roles, support workforce development across the region and generate hundreds of construction jobs. Established in 1992, the company’s Juncos site is one of the largest and most advanced biomanufacturing facilities in the world, producing biologic medicines distributed to more than 60 countries.